CL2007002081A1 -
IMMUNOGENIC HYBRID FUSION PROTEIN DERIVED FROM THE PROTEIN CS OF PLASMODIUM VIVAX; SEQUENCE OF NUCLEOTIDES CODED BY IT; PRODUCTION PROCEDURE; COMPOSITION THAT UNDERSTANDS IT; AND ITS USE TO TREAT MALARIA.
- Google Patents
IMMUNOGENIC HYBRID FUSION PROTEIN DERIVED FROM THE PROTEIN CS OF PLASMODIUM VIVAX; SEQUENCE OF NUCLEOTIDES CODED BY IT; PRODUCTION PROCEDURE; COMPOSITION THAT UNDERSTANDS IT; AND ITS USE TO TREAT MALARIA.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0614254.1Aexternal-prioritypatent/GB0614254D0/en
Priority claimed from GB0614473Aexternal-prioritypatent/GB0614473D0/en
Priority claimed from GB0614476Aexternal-prioritypatent/GB0614476D0/en
Application filed by Glaxosmithkline Biolog S A ThefiledCriticalGlaxosmithkline Biolog S A The
Publication of CL2007002081A1publicationCriticalpatent/CL2007002081A1/en
CL2007002081A2006-07-182007-07-17
IMMUNOGENIC HYBRID FUSION PROTEIN DERIVED FROM THE PROTEIN CS OF PLASMODIUM VIVAX; SEQUENCE OF NUCLEOTIDES CODED BY IT; PRODUCTION PROCEDURE; COMPOSITION THAT UNDERSTANDS IT; AND ITS USE TO TREAT MALARIA.
CL2007002081A1
(en)
IMMUNOGENIC HYBRID FUSION PROTEIN DERIVED FROM THE PROTEIN CS OF PLASMODIUM VIVAX; SEQUENCE OF NUCLEOTIDES CODED BY IT; PRODUCTION PROCEDURE; COMPOSITION THAT UNDERSTANDS IT; AND ITS USE TO TREAT MALARIA.